This has fostered the design of catalytic inhibitors of IDO1 (7–14; Figure 2) for the development of immunotherapeutic drugs that make tumor cells more vulnerable to T cell detection and destruction [17,18]. The gene discussed is IDO1; the disease is neoplasm.